Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors.
Jacob K JamisonMengxi ZhouEdward P GelmannLyndon LukSusan E BatesAndrea CalifanoTito FojoPublished in: The oncologist (2024)
In the treatment of relapsed or refractory abdominal NETs, entinostat 5 mg weekly led to prolonged SD and reduced the rate of tumor growth by 32% to 80% with an acceptable safety profile (ClinicalTrials.gov Identifier: NCT03211988).